Symptomology following mRNA vaccination against SARS-CoV-2.
СтатьяНаблюдательное исследованиеПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ebinger Joseph E, Lan Roy, Sun Nancy, Wu Min, Joung Sandy, Botwin Gregory J, Botting Patrick, Al-Amili Daniah, Aronow Harriet, Beekley James, Coleman Bernice, Contreras Sandra, Cozen Wendy, Davis Jennifer, Debbas Philip, Diaz Jacqueline, Driver Matthew, Fert-Bober Justyna, Gu Quanquan, Heath Mallory, Herrera Ergueen, Hoang Amy, Hussain Shehnaz K, Huynh Carissa, Kim Linda, Kittleson Michelle, Liu Yunxian, Lloyd John, Luong Eric, Malladi Bhavya, Merchant Akil, Merin Noah, Mujukian Angela, Nguyen Nathalie, Nguyen Trevor-Trung, Pozdnyakova Valeriya, Rashid Mohamad, Raedschelders Koen, Reckamp Karen L, Rhoades Kylie, Sternbach Sarah, Vallejo Rocío, White Shane, Tompkins Rose, Wong Melissa, Arditi Moshe, Figueiredo Jane C, Van Eyk Jennifer E, Miles Peggy B, Chavira Cynthia, Shane Rita, Sobhani Kimia, Melmed Gil Y, McGovern Dermot P B, Braun Jonathan G, Cheng Susan, Minissian Margo B
Аннотация
Despite demonstrated efficacy of vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of coronavirus disease-2019 (COVID-19), widespread hesitancy to vaccination persists. Improved knowledge regarding frequency, severity, and duration of vaccine-associated symptoms may help reduce hesitancy. In this prospective observational study, we studied 1032 healthcare workers who received both doses of the Pfizer-BioNTech SARS-CoV-2 mRNA vaccine and completed post-vaccine symptom surveys both after dose 1 and after dose 2. We defined appreciable post-vaccine symptoms as those of at least moderate severity and lasting at least 2 days. We found that symptoms were more frequent following the second vaccine dose than the first (74% vs. 60%, P < 0.001), with >80% of all symptoms resolving within 2 days. The most common symptom was injection site pain, followed by fatigue and malaise. Overall, 20% of participants experienced appreciable symptoms after dose 1 and 30% after dose 2. In multivariable analyses, female sex was associated with greater odds of appreciable symptoms after both dose 1 (OR, 95% CI 1.73, 1.19-2.51) and dose 2 (1.76, 1.28-2.42). Prior COVID-19 was also associated with appreciable symptoms following dose 1, while younger age and history of hypertension were associated with appreciable symptoms after dose 2. We conclude that most post-vaccine symptoms are reportedly mild and last <2 days. Appreciable post-vaccine symptoms are associated with female sex, prior COVID-19, younger age, and hypertension. This information can aid clinicians in advising patients on the safety and expected symptomatology associated with vaccination.